CD8A and cancer: We recently reported the results of an investigator-initiated, phase 1 trial of post-surgery adjuvant treatment of patients with resected pancreatic ductal adenocarcinoma (PDAC) with autogene cevumeran and the anti-PD-L1 CPI atezolizumab combined with standard-of-care adjuvant chemotherapy, showing substantial induction of high-magnitude, polyfunctional neoantigen-specific CD8+ effector T cells with longevity markers in a fraction of patients with cancer, which correlated with delayed PDAC recurrence25,26.